Sunday, September 20, 2026

Marathon Stock Plummets Over 9% In One Day: Find Out Why!

ViaNews Editorial Team

September 8, 2023

Marathon Stock Plummets Over 9% In One Day: Find Out Why!

(VIANEWS) - Marathon (NASDAQ: MARA) stock saw its shares plunge 9.95% at 11:10 EST on Friday after two consecutive sessions of gains, following which it had posted positive trends overall with the NASDAQ rising by 0.53% to EUR13,822.21. Even with its recent decrease, Marathon remains 37.83% below its 52-week high of EUR19.88.

About Marathon

Marathon Digital Holdings, Inc. is an industry-leading digital asset technology company specializing in mining of digital assets with a primary focus on blockchain ecosystem. Established in 2010 and based out of Fort Lauderdale, Florida initially as Marathon Patent Group Inc and later rebranding as Marathon Digital Holdings in February 2021; their primary market focus lies within United States markets where their role plays an integral part in creating digital assets that contribute towards expanding blockchain ecosystem.

Yearly Analysis

Based on the provided data, Marathon appears to be an investment with significant growth potential. Anticipated sales growth for 2017 stands at 226.2% and its EBITDA value of 14.23 suggests it is experiencing rapid expansion. At Marathon's current stock price of EUR11.13, investors appear uncertain about its long-term prospects or may anticipate negative news in the near future. This may indicate their fear. Investors looking for higher risk investments should carefully examine Marathon given its significant growth potential, but further investigation and research must be completed to fully comprehend their financial state and growth prospects before making any definitive investment decisions.

Technical Analysis

Marathon's stock has experienced significant fluctuations recently, trading below its 50-day moving average of EUR14.63 while trading above its 200-day moving average of EUR9.38. Additionally, Marathon reported volume was only 192,161,37, which represents 48.06% less than its average volume of 37,002,000. Marathon's intraday variation average for the past week, month, and quarter was positive 0.50%; negative 1.39% and positive 4.95%, respectively; its highest amplitude of average volatility during those time frames being 0.50% (last week), 5.87% (month), and 4.95% (quarter). According to the stochastic oscillator, an indicator for overbought and oversold conditions, Marathon's stock is currently considered "oversold" (=20). This suggests that its valuation may have fallen too far and could represent a potential buying opportunity; however, investors must conduct additional research prior to making any definitive investment decisions.

Quarter Analysis

Marathon's Investment Outlook Marathon's sales growth has been astounding, experiencing an incredible 770.4% surge during its current quarter and 403.2% growth over its next. This astounding success can be attributed to strong product offerings, marketing strategies, and overall business expansion by Marathon. Marathon's estimates for its current quarter and its next quarter growth rates are an expected 81.5 and 96.2 respectively, suggesting the company can maintain its strong expansionary trend in coming months. Marathon has seen year-on-year quarterly revenue growth of 228% year to date, reaching 174M over twelve trailing months. This impressive increase can be attributed to Marathon's ability to attract new customers while increasing sales to existing clients and branching out into new markets. Overall, Marathon appears to be an attractive investment opportunity with an optimistic growth potential. Investors should keep an eye on its financial performance over the coming quarters to ascertain if its growth can be maintained over time.

Equity Analysis

According to Marathon's financial data, its trailing twelve month EPS stands at EUR-4.07 - which indicates negative earnings per share and indicates the company is not producing profits for shareholders. Investors need this information because it reveals details about Marathon's financial health and performance. Additionally, the return on equity (ROE) for the twelve trailing months was negative at -76.14% - another warning sign to investors that indicates no profits have been generated relative to shareholder equity. Furthermore, this negative ROE suggests that assets may not be utilized efficiently enough by management in order to generate returns which is an issue for shareholders. Overall, these financial indicators show that Marathon's profitability is currently negative, which may signal danger for potential investors. Before making any definitive investment decisions based on this information alone, it is vitally important that investors combine it with other quantitative and qualitative elements before making their choice.

More news about Marathon (MARA).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com